Hayley Crawford is the Virology Project Leader at Integral Molecular and manages the company’s extensive Reporter Virus Particle (RVP) portfolio. She spearheads all aspects of the SARS-CoV-2 RVP product cycle—from product development through manufacturing and quality control—for current and emerging strains. Prior to joining Integral Molecular, Dr. Crawford was a postdoctoral researcher at Oxford University, where she worked on designing HIV vaccines using CD8+ T cell epitope constructs. She obtained her PhD from Oxford University and has over a decade of experience in virology and immunology.